Avacta extends Pall Life Sciences’ Optim 1000 distribution agreement to include India
27 September 2012 | By kdm communications limited
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech market...
List view / Grid view
27 September 2012 | By kdm communications limited
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech market...
27 September 2012 | By CI Precision
Actelion Pharmaceuticals Ltd, has endorsed CI SADE weight sorters...
26 September 2012 | By GlaxoSmithKline
GSK announces the following changes to its Board and Committee structure...
26 September 2012 | By GlaxoSmithKline
Japanese New Drug Application (JNDA) submitted for COPD and asthma....
25 September 2012 | By Cisbio Bioassays
Cisbio Bioassays announces the launch of its epigenetics toolbox for use in drug discovery research...
25 September 2012 | By Boehringer Ingelheim / Eli Lilly & Company
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present data for three molecules, including two investigational compounds, from their Diabetes Alliance portfolio at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, 1–5 October 2012. Now in its second year, the Boehringer-Lilly Alliance…
24 September 2012 | By Renishaw plc
Celebrating 20 years of Renishaw Raman...
24 September 2012 | By Novo Nordisk
Novo Nordisk invests an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing....
24 September 2012 | By
Data on 13 of its investigational and approved products will be presented at ESMO 2012...
24 September 2012 | By Boehringer Ingelheim / Eli Lilly and Company
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a Positive Opinion from the European Medicines Agency’s (EMA) medicinal committee recommending expanding the therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin). If approved by the European Commission, this will expand the indicated use of Trajenta® by…
24 September 2012 | By Roche
For the treatment of women with recurrent, platinum-sensitive ovarian cancer...
24 September 2012 | By Pfizer
For the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation...
24 September 2012 | By Novo Nordisk
Novo Nordisk has been ranked number four on the Science 2012 Top Employer list – up from ninth place last year...
24 September 2012 | By Elan Corporation
Mr. Hasler is currently a non-executive director of the Company and he will retire from the board of directors of the Company...
21 September 2012 | By Pittcon
The Registration Committee is pleased to announce that conferee registration is now open for Pittcon 2013, which will be held March 17-21, 2013...